Clinical Trials Browser

Ovarian Neoplasms

NCT05077384 2025-09-16

Open-label Study of Surufatinib in Japanese Patients

Phase 1/2 Completed

36 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT05218889 2024-12-31

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1/2 Recruiting

90 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05832892 2024-06-14

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Phase 1/2 Unknown

41 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05093322 2024-06-07

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Phase 1/2 Completed

13 enrolled 17 charts

LymphoidSarcoma

Lymphoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT06255262 2024-02-13

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Unknown

30 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05882630 2023-05-31

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Phase 1/2 Not yet recruiting

39 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Phase 1/2 Unknown

45 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05747729 2023-02-28

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Phase 1/2 Unknown

60 enrolled

Endocrine

Carcinoma, Neuroendocrine

NCT04996771 2022-11-14

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

Phase 1/2 Unknown

88 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05590572 2022-10-21

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Phase 1/2 Not yet recruiting

148 enrolled

Sarcoma

Osteosarcoma

NCT04929652 2021-06-18

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer

Phase 1/2 Unknown

48 enrolled

Gastrointestinal

Advanced Colorectal Cancer

Clinical Trials

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Open-label Study of Surufatinib in Japanese Patients

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer